Probing SARS-CoV-2-positive plasma to identify potential factors correlating with mild COVID-19 in Ghana, West Africa
© 2022. The Author(s)..
BACKGROUND: West Africa has recorded a relatively higher proportion of asymptomatic coronavirus disease 2019 (COVID-19) cases than the rest of the world, and West Africa-specific host factors could play a role in this discrepancy. Here, we assessed the association between COVID-19 severity among Ghanaians with their immune profiles and ABO blood groups.
METHODS: Plasma samples were obtained from Ghanaians PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive individuals. The participants were categorized into symptomatic and asymptomatic cases. Cytokine profiling and antibody quantification were performed using Luminex™ multiplex assay whereas antigen-driven agglutination assay was used to assess the ABO blood groups. Immune profile levels between symptomatic and asymptomatic groups were compared using the two-tailed Mann-Whitney U test. Multiple comparisons of cytokine levels among and between days were tested using Kruskal-Wallis with Dunn's post hoc test. Correlations within ABO blood grouping (O's and non-O's) and between cytokines were determined using Spearman correlations. Logistic regression analysis was performed to assess the association of various cytokines with asymptomatic phenotype.
RESULTS: There was a trend linking blood group O to reduced disease severity, but this association was not statistically significant. Generally, symptomatic patients displayed significantly (p < 0.05) higher cytokine levels compared to asymptomatic cases with exception of Eotaxin, which was positively associated with asymptomatic cases. There were also significant (p < 0.05) associations between other immune markers (IL-6, IL-8 and IL-1Ra) and disease severity. Cytokines' clustering patterns differ between symptomatic and asymptomatic cases. We observed a steady decrease in the concentration of most cytokines over time, while anti-SARS-CoV-2 antibody levels were stable for at least a month, regardless of the COVID-19 status.
CONCLUSIONS: The findings suggest that genetic background and pre-existing immune response patterns may in part shape the nature of the symptomatic response against COVID-19 in a West African population. This study offers clear directions to be explored further in larger studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
BMC medicine - 20(2022), 1 vom: 03. Okt., Seite 370 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tapela, Kesego [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.10.2022 Date Revised 25.01.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12916-022-02571-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34700136X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34700136X | ||
| 003 | DE-627 | ||
| 005 | 20231226032807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12916-022-02571-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM34700136X | ||
| 035 | |a (NLM)36184636 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tapela, Kesego |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Probing SARS-CoV-2-positive plasma to identify potential factors correlating with mild COVID-19 in Ghana, West Africa |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2022 | ||
| 500 | |a Date Revised 25.01.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: West Africa has recorded a relatively higher proportion of asymptomatic coronavirus disease 2019 (COVID-19) cases than the rest of the world, and West Africa-specific host factors could play a role in this discrepancy. Here, we assessed the association between COVID-19 severity among Ghanaians with their immune profiles and ABO blood groups | ||
| 520 | |a METHODS: Plasma samples were obtained from Ghanaians PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive individuals. The participants were categorized into symptomatic and asymptomatic cases. Cytokine profiling and antibody quantification were performed using Luminex™ multiplex assay whereas antigen-driven agglutination assay was used to assess the ABO blood groups. Immune profile levels between symptomatic and asymptomatic groups were compared using the two-tailed Mann-Whitney U test. Multiple comparisons of cytokine levels among and between days were tested using Kruskal-Wallis with Dunn's post hoc test. Correlations within ABO blood grouping (O's and non-O's) and between cytokines were determined using Spearman correlations. Logistic regression analysis was performed to assess the association of various cytokines with asymptomatic phenotype | ||
| 520 | |a RESULTS: There was a trend linking blood group O to reduced disease severity, but this association was not statistically significant. Generally, symptomatic patients displayed significantly (p < 0.05) higher cytokine levels compared to asymptomatic cases with exception of Eotaxin, which was positively associated with asymptomatic cases. There were also significant (p < 0.05) associations between other immune markers (IL-6, IL-8 and IL-1Ra) and disease severity. Cytokines' clustering patterns differ between symptomatic and asymptomatic cases. We observed a steady decrease in the concentration of most cytokines over time, while anti-SARS-CoV-2 antibody levels were stable for at least a month, regardless of the COVID-19 status | ||
| 520 | |a CONCLUSIONS: The findings suggest that genetic background and pre-existing immune response patterns may in part shape the nature of the symptomatic response against COVID-19 in a West African population. This study offers clear directions to be explored further in larger studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ABO blood groups | |
| 650 | 4 | |a Antibodies | |
| 650 | 4 | |a Asymptomatic | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Eotaxin | |
| 650 | 4 | |a West Africa | |
| 650 | 7 | |a ABO Blood-Group System |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Interleukin 1 Receptor Antagonist Protein |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Interleukin-8 |2 NLM | |
| 700 | 1 | |a Oyawoye, Fatima O |e verfasserin |4 aut | |
| 700 | 1 | |a Olwal, Charles Ochieng' |e verfasserin |4 aut | |
| 700 | 1 | |a Opurum, Precious C |e verfasserin |4 aut | |
| 700 | 1 | |a Amponsah, Jones Amo |e verfasserin |4 aut | |
| 700 | 1 | |a Segbedzi, Kekeli Aku Lumor |e verfasserin |4 aut | |
| 700 | 1 | |a Tetteh, Becky |e verfasserin |4 aut | |
| 700 | 1 | |a Kumi-Ansah, Frederick |e verfasserin |4 aut | |
| 700 | 1 | |a Mutungi, Joe K |e verfasserin |4 aut | |
| 700 | 1 | |a Obodai, Evangeline |e verfasserin |4 aut | |
| 700 | 1 | |a Amoako, Emmanuella |e verfasserin |4 aut | |
| 700 | 1 | |a Agyemang, Seth |e verfasserin |4 aut | |
| 700 | 1 | |a Ndam, Nicaise Tuikue |e verfasserin |4 aut | |
| 700 | 1 | |a Ampofo, William Kwabena |e verfasserin |4 aut | |
| 700 | 1 | |a Rayner, Julian C |e verfasserin |4 aut | |
| 700 | 1 | |a Awandare, Gordon A |e verfasserin |4 aut | |
| 700 | 1 | |a Paemka, Lily |e verfasserin |4 aut | |
| 700 | 1 | |a Bediako, Yaw |e verfasserin |4 aut | |
| 700 | 1 | |a Quashie, Peter Kojo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC medicine |d 2003 |g 20(2022), 1 vom: 03. Okt., Seite 370 |w (DE-627)NLM143503421 |x 1741-7015 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2022 |g number:1 |g day:03 |g month:10 |g pages:370 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12916-022-02571-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2022 |e 1 |b 03 |c 10 |h 370 | ||